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INTRODUCTION 
Ankylosing spondylitis (AS) is an inflammatory disorder of unknown cause that 
primarily involves the axial skeleton, though peripheral joints and exta-articular 
structures are also involved. It usually manifests in the second to third decade and has a 
male to female ratio varying in literature from 4-10:1, however most recent studies show 
a ratio between 5:1 to 3:1(1-3). Enthesitis is a classical feature of this disease. 
Subchondral bone marrow edema, infiltration of lymphocytes and macrophages, and 
synovitis have been seen in early stages of this disease in the sacroiliac as well as 
peripheral joints. These processes lead to pannus formation similar to rheumatoid 
arthritis, joint erosion and ultimately new bone formation. Even though new bone 
formation is one of the cardinal features of the disease, osteoporosis has been found to 
occur in patients with AS(4).  
              The prevalence of osteoporosis in AS among Caucasians has been found in 
various studies to range from 4.3 to 31%(5-10). These studies utilized various means of 
assessing bone mineral density (BMD). It has been found that the ideal measure for 
osteoporosis in AS is the Dual energy X ray absorptiometry (DEXA) of femoral neck and 
a lateral projection of L3 vertebra(11, 12). In recent times however Quantitative CT 
(QCT) has been proposed as an alternative and has been shown to correlate well with 
BMD(10). QCT may in fact be able to pick up osteoporosis at an earlier stage than 
DEXA, however it is more expensive and less well standardized than DEXA(13).  
                  The pathogenesis of osteoporosis in AS, has not been completely elucidated. 
In later stages of the disease immobilization plays an important role, however 
 2
osteoporosis begins early in AS and has been thought to be related to effects of 
inflammatory cytokines on osteoclasts and bone turnover(14). Studies have implicated 
Tumor Necrosis Factor α (TNFα) in the pathogenesis of AS and clinical trials have 
shown benefit with TNFα blockers. The exact role of TNFα has not been described but 
studies show that TNFα causes increased osteoclast activation and may hence lead to 
osteoporosis. The RANK/RANKL/OPG system which plays a pivotal role in osteoclast 
differentiation and activation may explain the pathogenesis of osteoporosis in AS(15). 
Studies are however conflicting on the relationship between markers of bone turnover 
and changes in BMD with some studies showing increased turnover, while others showed 
no change in the same(5, 12, 14). Thus, the precise mechanisms underlying osteoporosis 
in AS, remain to be elucidated. 
                    Despite the fact that osteoporosis is a recognized complication of AS and can 
lead to increased fracture risk – up to five times more than expected, there are no 
guidelines concerning the diagnosis and treatment of osteoporosis in AS. An audit of 
diagnosis and treatment of this disorder by rheumatologists in England, revealed grossly 
inadequate awareness about the need to screen for osteoporosis and also about 
appropriate treatment(16).  
                  There is therefore, a need to evolve common guidelines for screening and 
treatment of osteoporosis in patients with AS. Studies are also required to look at 
relationship between duration of disease and occurrence of osteoporosis. Some studies 
have shown a positive correlation between duration and osteoporosis, however these 
studies have been done in Western countries and on patients who were for the most part 
not on second line therapy. It has been observed that among Indians, there is more 
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appendicular skeleton involvement, which may represent more severe disease. With more 
data, the ideal time to screen for osteoporosis can be determined. Establishing various 
clinical correlates of osteoporosis in AS, including indices such as Bath Ankylosing 
Spondylitis Disease Activity Index (BASDAI) and Bath Ankylosing Spondylitis 
Functional Index (BASFI) may be helpful as clinical predictors. As a corollary, the effect 
of treatment on the occurrence of osteoporosis may suggest a causal relationship between 
osteoporosis and inflammatory activity.  
                 This study is the first ever attempt to determine the prevalence of osteoporosis 
in Indian patients of AS and to assess whether demographic factors, duration of disease, 
disease activity or treatment correlate with the occurrence of osteoporosis. 
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OBJECTIVES OF THE STUDY 
 
1. To determine the occurrence of osteoporosis among a cohort of patients with 
Ankylosing Spondylitis(AS).  
 
2. To assess whether the following disease indices - the BASDAI(Bath Ankylosing 
Spondylitis Disease Activity Index), BASFI (Bath Ankylosing Spondylitis 
Functional Index), or BAS-G (Bath Ankylosing Spondylitis Global Index) have a 
correlation with  osteoporosis in AS. 
 
3. To assess if demographic factors, disease duration, treatment with steroids, 
DMARDS or laboratory parameters of inflammation have an association with 
occurrence of osteoporosis in AS.  
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REVIEW OF LITERATURE 
 
Ankylosing Spondylits 
Ankylosing spondylitis (AS) is a chronic inflammatory disease that predominantly affects 
young men and is associated with the HLA B27 antigen in over 90% of cases(1). Patients 
generally present in young adulthood. Men are definitely more affected than women (1-
3). There is also a rough correlation between the prevalence of HLA B27 and the 
incidence and prevalence of this disease in a specific population. Presence of HLA B27 
in an individual makes one 40 times more susceptible to develop AS in one’s life time, as 
compared to HLA B27 negative people (1). However, there are certain sub-types of B27 
such as B27 06, which may in fact be protective against AS. These have been found to be 
more common in certain races such as blacks, but are uncommon in Indians(17).  
The most important symptom of AS is inflammatory back pain, caused by sacroiliitis. 
Bilateral sacroiliitis is the main diagnostic criterion in the modified NewYork criteria 
set(18). Other sites of involvement include the spine, peripheral joints, and entheses 
(capsules, ligaments, and tendons). Extra-articular manifestations vary widely in terms of 
both frequency and severity. Inflammatory enthesopathy progressing to ossification and 
ankylosis is the pathologic basis for the disease. Despite advances in technology, the 
etiology and pathogenesis of this disorder remain elusive.  Environmental factors may 
also play a key role, especially bacteria which could serve as a trigger in susceptible 
hosts. This is supported by the observation that B 27 transgenic mice do not develop 
spondyloarthritis if raised in a bacteria free environment (1).  
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Osteoporosis 
Osteoporosis is a disorder of increased bone fragility and low bone mass with a 
consequent increase in fracture risk(19). It is most commonly seen in the setting of 
postmenopausal women. However, there are several secondary causes, which include the 
inflammatory arthritides. Several factors have been implicated in its pathogenesis 
including – declining estrogen levels, genetic background, nutritional status, alterations in 
Parathyroid hormone (PTH) levels and growth hormone – Insulin like growth factor 
(IGF) axis, mechanical strain and factors related to risk of falling. Clinicians must rely on 
measurements of BMD to diagnose this disorder. A 10% decrease in BMD (1 SD below 
the mean) at any site confers a 1.6 to 2.6 Relative risk (RR) of hip fracture and a 1.7 to 
2.3 RR of vertebral fracture. BMD is reported as two scores namely, Z score and T score. 
The Z score compares the patients BMD with that of age-matched controls. The T score 
compares the patients BMD to the mean of a healthy reference population thought to 
represent the peak bone mass. A T score of –2.5 and below meets WHO criteria for 
osteoporosis and a score between –2.5 and –1 represents osteopenia(20).  
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The Magnitude of the Problem  
Diffuse osteoporosis responsible for loss of bone strength is a recently reported feature of 
AS. The bone loss predominates at the spine. Late in the disease, vertebral fractures 
constitute a rare but non-negligible source of morbidity and mortality related mainly to 
neurological compromise(4).  
The prevalence of osteoporosis in AS has been assessed in several studies and varies 
from 4.3% to 31%. The prevalence has been found to depend on several factors – disease 
duration, age, sex, disease activity, presence of syndesmophytes and also depends on the 
method used to assess osteoporosis. A summary of all studies undertaken to assess BMD 
in AS patients is shown in Table 1. Most of these studies were done in Caucasian 
populations. The studies encompass the entire gamut of the disease – in terms of duration, 
sex, activity and treatment. However no data is available from India. The various factors 
affecting osteoporosis are discussed below. 
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Table 1. Summary of studies to assess osteoporosis in patients with AS 
Authors 
[reference]  
 
Number 
of 
Patients 
Mean age, sex 
ratio, mean 
disease 
duration 
Measurement 
technique 
 
BMD, lumbar 
spine 
BMD, 
femoral 
neck 
BMD, 
radius 
Devogelaer 
et al 
(21) 
  
 
70 
 
 
 
10 
39 years, 60 M, 
10 F, 
15 years 
 
8 M, 2 F 
DXA 
 
 
 
QCT 
M: decreased  
F: not 
decreased 
 
Decreased 
ND 
 
 
 
    - 
No 
Difference 
Bronson et 
al (12) 
 
15 23-74 years, 15 
M , not 
specified 
DXA Normal Decreased ND 
Donnelly et 
al. (22) 
 
87 44 years, 62 M, 
25 F, 16 years 
DXA M: decreased 
F: not 
decreased 
Decreased ND 
Mullaji and 
Ho (23) 
 
 
33 37,8 years, 27 
M, 6 F, M1: 
8.7 years; M2: 
11.7 years; 
F: 6.8 years 
DXA M1:decreased 
M2:normal 
F:Decreased 
Decreased 
in all 
groups 
ND 
El 
Maghraoui 
et al. (5) 
80 36.7 years, 52 
M, 28 F, 8.7 
years 
DXA Osteopenia: 
31%, 
Osteoporosis: 
18.7% 
Osteopenia
: 41.2%, 
osteoporosi
s: 13.7% 
ND 
 
Toussirot et 
al (7) 
 
 
71 39.1 years, 49 
M, 22 F, 10.6 
years 
DXA Osteopenia: 
32.4%, 
Osteoporosis: 
14.1% 
Osteopenia
: 22.5%, 
osteoporosi
s: 4.3% 
ND 
El 
Maghraoui 
et al. (24) 
37 36.4 years, 37 
M, 6.8 years 
QCT Osteopenia: 
29.7%, 
Osteoporosis: 
27% 
       _      _  
Juanola et al 
(6) 
18 36.7 years, 18 
F, 15.1 years 
DXA Osteopenia 
11% 
Osteoporosis 
None 
No 
difference 
ND 
Karberg et 
al (10) 
103 66 M, 37 F,  DXA 
 
 
 
 
DEQCT 
 
 
 
Osteopenia 
31% 
Osteoporosis 
14% 
 
Osteopenia 
44% 
Osteoporosis 
11% 
Osteopeni\
a  52% 
Osteoporos
is 24% 
ND 
M, males; F, females; BMD, bone mineral density; DPA, dual-photon absorptiometry; DXA, dual-energy 
X-ray absorptiometry; QCT, quantitative computed tomography; ND, not done. 
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Factors affecting occurrence of the problem 
Sex 
Studies have shown that osteoporosis in AS is more common among male patients (21). 
One study also reported a higher prevalence of vertebral fractures in males with AS (25). 
A higher prevalence of osteoporosis in men with AS as compared to females, may be 
related to more severe disease, and the presence of an androgen deficiency (28).  
 
Duration of Disease 
It has been shown that femoral BMD correlates inversely with disease duration(10). The 
lumbar spine BMD however increases with advancing disease(26). This is due to 
extraspinal ossification causing an artefactual increase. A lateral projection of L3 vertebra 
may enable us to get a true BMD of the spine in advanced disease(12). A new method, 
which has shown promise is the QCT and, using this it was found that spine BMD also 
correlates inversely with disease duration(10). Using femoral BMD, the prevalence of 
osteoporosis in patients with AS for less than 5 years duration was found to be 11%, as 
compared to 29% in those with disease duration of more than 10 years(10). Another 
study in Brazil demonstrated a positive correlation between BMD at lumbar spine, and 
hip with disease duration (26). Thus prolonged duration of disease is a definite predictor 
for osteoporosis. 
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Disease activity 
In a study on 80 patients with AS, Maghroui et al showed that increased disease activity 
correlated with elevated markers of bone resorption (5). Similar relationships have been 
demonstrated in several other studies(9). However none of these studies demonstrated a 
relationship between clinical disease activity and BMD. In one study it was shown that, 
BMD did not differ between patients with active and inactive disease (26). It has also 
been shown that inflammatory markers such as ESR and CRP do not correlate with 
BMD(26). Thus the relationship of disease activity with osteoporosis remains unclear. 
Further data may help in clarifying this relationship. If such a relationship exists, disease 
activity may serve as one of the predictors for osteoporosis in AS.  
 
 
Awareness of the Problem 
In a study conducted among rheumatologists in the UK, out of 310 respondents only 
31.6% assessed bone mass as part of routine management of AS. DEXA was the method 
of choice for assessing osteoporosis, however, most of them did not wish to assess hip 
BMD. When given case scenarios of patients with AS and osteoporosis, only 75% said 
that they would use a bisphosphonate for treatment(16). This illustrates the lack of 
awareness regarding this common complication of AS.  
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Ideal tool to assess BMD in AS 
DEXA is a precise, reproducible and standardized tool to measure BMD. However, as 
mentioned above, lumbar spine BMD in advanced AS shows a misleading increase due to 
presence of bridging syndesmophytes (10, 26). Thus in mild and moderate AS, spine 
BMD shows reduction, but in severe disease it progressively increases. Femoral neck 
BMD however has been shown to have an inverse relationship with disease duration and 
severity and is reduced in all patient groups(11). The lateral decubitus projection of L3 is 
more sensitive than posteroanterior projection in detecting osteoporosis in moderate and 
severe AS(12). Thus this may be an alternative to femoral neck BMD.  
Another method that has been tried is the Quantitative Computerized Tomography 
(QCT). This has been found to be of use in patients with severe disease and extraspinal 
ossification in whom DEXA shows falsely high values in spine BMD. In a study on 103 
patients of AS with disease duration more than 10 years, spinal DEQCT showed 
osteoporosis in 18% of them, while only 4% were osteoporotic by DEXA. However, in 
the same cohort, femoral DEXA showed osteoporosis in 29%(10). QCT measurements 
have still not been standardized and are not available as widely as DEXA. Also there is a 
higher radiation dose in the case of QCT. QCT may be of use in patients with advanced 
disease, or in patients with hip arthroplasty. 
In view of this data, the ideal tool would be a femoral neck BMD. Where available, a 
Lateral projection of L3 may also be of use, since it has been shown that this vertebra is 
the first site of bone loss in AS(14).  
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Validity of DEXA in Indian setting  
BMD as measured by DEXA is considered the gold standard for diagnosing osteoporosis. 
A drawback using this method in our setup maybe that the machine used for these 
measurements utilizes Caucasian controls to calculate and report T scores. The issue of 
whether there is a difference between the BMD of Indian and Caucasian populations has 
been addressed to some extent. Two studies have shown that normal Indian women had 
lower BMD as compared to Caucasian controls. Another necropsy based study however 
showed no difference between Indians and Caucasian controls(27).  In a recent study 
from AIIMS – men and women with optimal sunlight exposure, diet and physical activity 
were evaluated to assess biochemical parameters of bone metabolism and BMD. This 
study revealed that all the subjects had normal calcium, phosphorus, alkaline 
phosphatase, 25 OH vitamin D levels and PTH. However measurement of BMD revealed 
that 35-50% of men and 14-32% of women were osteopenic at different sites. In addition 
10% of men had osteoporosis at the lumbar spine using western controls (28). Since these 
men and women had normal biochemical parameters, optimum diet, sunlight and 
physical activity, the difference in BMD may be related to ethnicity. Thus there is a need 
to establish normative data for Indians. Thus determination of T scores in relation to the 
Indian subjects may provide a more accurate picture of the prevalence of osteoporosis 
and osteopenia in our population, than comparison with Caucasian controls.  
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Mechanism of Osteoporosis in AS 
The mechanism underlying osteoporosis in AS has not been conclusively elucidated, 
however several factors may play a role in this process. Earlier it was thought that 
immobilization and lack of physical activity were the main factors responsible for 
osteoporosis in AS. It has however been shown that the development of osteoporosis is a 
multi-factorial process. The following mechanisms have been proposed  
 
1. Immobility related to pain and stiffness early in the disease and to spinal ankylosis 
later on, may cause osteoporosis. In late AS, the mechanical support provided by 
extraspinal ossification may divert gravitational, motional and compressive stresses away 
from vertebral trabeculae, resulting in diminished trabecular density, as predicted by 
Wolf’s Law. However, established osteoporosis has been found in patients who had early 
disease without noticeable functional impairment(14). Thus in such cases systemic 
factors are likely to be of more importance.  
 
2. Glucocorticoids, which are widely used to treat inflammatory joint disease, are known 
to promote bone loss. However, glucocorticoids are rarely used to treat AS, and 
osteoporosis has been found in series of glucocorticoid-naïve patients with AS, 
rheumatoid arthritis, or systemic lupus erythematosus. Nonsteroidal anti-inflammatory 
drugs, also used in inflammatory joint disease, have not been shown to adversely affect 
bone in humans, although a few studies in animals suggested an ability to promote bone 
loss. 
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3.Although androgen deficiency has been suggested in AS patients, several studies have 
found similar incidences of hormone level abnormalities in patients and controls(29).  
 
4.Decreased BMD at the femoral neck in early disease suggests that systemic mediators 
may be involved in the pathogenesis of osteoporosis in AS. Several cytokines including 
TNF α and Tumor necrosis factor β (TNF β) as well as both murine and porcine 
interleukin 1(IL1) have been found to be potent osteoclast activating factors (OAF) in 
vitro. Serum levels of interleukin-6 (IL-6) and TNF α have been found to be higher in 
patients with AS than in patients with non-inflammatory back pain.  
In AS, positive correlation was found between levels of IL-6 and TNF α and measures of 
disease activity and severity(30). However, measurements of bone turnover markers have 
yielded highly conflicting results. Inflammation of the entheses and synovium may result 
in increased release of pro-inflammatory cytokines, whose deleterious effects on bone 
metabolism have been established(31). TNF α, IL-1, and IL-6 induce bone metabolism 
imbalances in animals and humans(31, 32). Thus, in several studies, significant 
correlations were found between bone turnover markers (pyridinoline, deoxypyridinoline, 
C- and N-telopeptide crosslinks, and osteocalcin) and the levels of pro-inflammatory 
cytokines or their markers (erythrocyte sedimentation rate and C-reactive protein) used in 
clinical practice(8, 9, 14). Individual studies have found reduced markers of bone 
formation (osteocalcin) in patients with AS(8). This suggests that there is an uncoupling 
of the processes of bone formation and resorption leading to a resultant decrease in bone 
mass. 
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5.Another important factor seems to be the RANKL/RANK/OPG system. Studies have 
shown that Osteoprotegerin(OPG),(a molecule which neutralizes Receptor Activator of 
Nuclear Factor kB Ligand (RANKL)) are lower in patients with AS who have 
osteoporosis(9). RANKL is a molecule that binds to and activates RANK present on 
osteoclasts. This subsequently leads to osteoclast activation and may subsequently 
produce osteoporosis. Recent studies have shown that higher RANKL levels and higher 
RANKL/OPG ratio are seen in AS patients with lower BMD(15). In other inflammatory 
conditions associated with osteoporosis, it has been shown that RANKL may cause an 
autocrine production of TNF α leading to further osteoclast activation(33). This 
mechanism may be of importance in AS as well.  This data suggests an important role for 
this mechanism in producing osteoporosis in AS.  
 
6. Clinically silent bowel disease may contribute to the development of bone loss, 
according to a small number of studies showing bowel lesions in nearly two-thirds of 
patients with AS investigated routinely (34, 35). These lesions may lead to decreased 
calcium and vitamin D absorption leading to osteoporosis.  
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Figure 1. 
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Biochemical Markers of Bone Metabolism 
Markers of Bone formation 
Serum Osteocalcin 
Serum osteocalcin is a very sensitive and specific marker for bone formation. 
Oseteocalcin synthesis is stimulated by Parathyriod Hormone and 1,25-dihydroxy 
vitamin D3. Serum osteocalcin levels are decreased in hypoparathyroidism, in clinical 
situations leading to low turnover osteoporosis, and in patients receiving 
glucocorticoids(36, 37). Circulating levels of serum osteocalcin have been shown to be 
reduced in patients with AS, suggesting reduced bone formation(14). In one study there 
was a negative correlation between osteocalcin levels and femoral neck BMD(8). 
However some authors have reported unaltered serum osteocalcin levels in AS.  
Insulin-like Growth Factor 1 (IGF-1) and IGF Binding Protein 3 (IGFBP3)  
IGF-1 mediates the effect of growth hormone (GH) at the tissue level, including bone. Its 
binding protein IGFBP3, can increase the anabolic action of IGF-1 in bone, and together 
their levels reflect osteoblast function(38).  
IGF-1 levels are decreased in postmenopausal women and idiopathic male osteoporosis 
and are directly related to axial bone density in postmenopausal women. Enhanced bone 
formation occurs post treatment with IGF-1 in idiopathic male osteoporosis(39).  
IGFBP3 levels have been found to be reduced in AS, and a positive correlation between 
the concentration of osteocalcin and IGF-1 has also been reported. The levels of IGFBP3 
vary inversely with ESR, suggesting that inflammation may impair production of 
IGFBP3 in response to GH. The reduced levels may then diminish the activity of IGF-1 
in AS(40).  
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Markers of Bone Resorption 
Positive correlations between the concentrations of urinary markers of bone resorption 
pyridinoline (Pyr), deoxypyridinoline (D-Pyr) and C-telopeptide with morning stiffness, 
radiological hip score and inflammatory markers like ESR and CRP have been found(14). 
The latter was most marked among the patients with most active inflammation. Schober 
index and fat mass percentage have been shown to correlate negatively with these 
resorption markers(12).  
 Osteoprotegerin 
Osteoprotegerin(OPG) is produced in a variety of tissues, cell types and cell lines. OPG 
binds and neutralizes RANKL, and thus prevents RANKL activation of RANK. In vivo 
over-expression of OPG in transgenic mice or administration of OPG to normal rodents 
inhibited osteoclastogenesis, osteoclast activation and bone resorption, resulting in 
osteoporosis. Since activated T cells produce RANKL, the RANKL/RANK/OPG system 
may play an important role in pathogenesis of osteoporosis in inflammatory arthritides.  
In a study on 264 AS patients it was shown that OPG levels were significantly lower in 
patients with AS than in controls. The patients were also found to have lower BMD as 
compared to the controls(9). A more recent study also showed that the levels of RANKL 
were higher in patients with AS. The RANKL/OPG ratio was higher in patients who had 
a lower BMD (15). Thus a decrease in OPG production or an increase in RANKL may be 
responsible for increased osteoclast activity and subsequent osteoporosis in AS.    
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Fracture Rates in patients with AS 
 Vertebral fractures 
Vertebral fracture rates in AS from several studies have ranged from 0% to 20% (22, 25, 
41, 42). In 1971, Hansen et al, reported findings from routine radiological studies in 50 
patients with AS, 10 females and 40 males, aged 24–79 years (41). Disease duration 
ranged from 3 months to 50 years. Additional risk factors for osteoporosis such as long-
term glucocorticoid therapy were present only in a few older patients. Two (4%) patients 
had vertebral fractures in this series. A study reported by Raltson et al. in 1990 evaluated 
the vertebral fracture rate in 111 AS patients (98 males and 13 females) with a mean age 
of 41 years and a mean disease duration of 17 years(41). Vertebral fractures and vertebral 
biconcave deformities were detected using a standardized vertebral height index 
determined on lateral radiographs of the spine. Abnormalities were found in 20 (18%) 
patients (vertebral fractures in 15 and biconcave deformities in five). Similarly, Donnelly 
et al. found vertebral fractures in nine of 87 (10.3%) patients with spondyloarthropathy 
(AS, n = 2; psoriatic arthritis, n = 7; Reiter’s syndrome, n = 1; enteropathic arthropathy, n 
= 7)(43). The population was composed of 62 males and 25 females with a mean age of 
44 years and a mean disease duration of 16 years. The thoracic segment was the main site 
of vertebral fractures. In a more recent study by Mitra et al, out of 56 patients with mild 
AS 19.6% had a vertebral fracture as compared to only 2% in controls(14). In this study 
vertebral fractures did not correlate with biochemical markers of bone metabolism. A 
recent study also showed that femoral inter-trochanteric BMD correlated with vertebral 
fractures(44).  
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Peripheral fractures 
Patients with AS had similar peripheral fracture rates as did the population at large in a 
study by Cooper et al (45). 
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Treatment of Osteoporosis in AS 
Despite the large body of research on osteoporosis in patients with AS, few studies have 
investigated treatment options. Management of osteoporosis can be divided into 
preventive and therapeutic approaches. The different treatment options are listed below 
1. Bisphosphonates 
There is currently no data specifically addressing the issue of treatment of osteoporosis in 
AS. The bisphosponates are compounds that inhibit bone resorption in a dose dependent 
manner in patients with involutional osteoporosis. Intermittent cyclical etidronate therapy 
increases BMD by 6% over a period of 2 years, with a resultant decrease in the rate of 
new vcrtebral compression fractures. Alendronate increases BMD in both the axial and 
appendicular skeleton. The annual rate of increase of BMD is 3% at lumbar spine and 2%  
at femoral neck. The risk of developing fractures at the hip, spine and wrist is decreased 
by about 50%. Zoledronate is an injectible bisphosphonate, which has been shown to be 
as effective as alendronate in treating post-menopausal osteoporosis (46). It requires 
dosing only once a year and may be a convenient treatment option in patients with poor 
drug compliance. Monthly pamidronate infusions provided symptom relief in two studies 
of patients with AS. The first was an open label study and the other was a randomized 
control trial (47, 48). However the effects of BMD were not assessed in either of these 
studies. Randomized controlled trials to assess the efficacy of bisphosphonates in 
maintaining BMD and reducing the development of osteoporotic vertebral compression 
fractures and femoral neck fractures in patients with AS are required.  
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2. Testosterone  
Both male patients with AS and 16% of men with vertebral compression fractures exhibit 
hypogonadism. Although testosterone treatment increases BMD in hypogonadal men, 
trials are required to determine the efficacy of this treatment in patients with AS.  
 
3.TNF α inhibitors 
Since it is apparent that the inflammation, which is the cause of the disease is also the 
main factor responsible for osteoporosis, treatment targeting control of inflammation 
would also help to stop bone loss(49).  In the future these may become the treatment of 
choice given their dramatic efficacy in controlling disease symptoms.  
 
Monitoring of Treatment 
As in osteoporosis without AS, assessments of whether treatment is effective or condition 
is worsening are necessary. However trials have not established the appropriate 
investigation or interval for monitoring.  
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PATIENTS AND METHODS 
 
Study Setting  
The study was conducted in Christian Medical College Hospital, Vellore, a 1800 
bedded tertiary care teaching hospital in South India. Patients for the study were drawn 
from the out patient clinics of the Department of Medicine II and Rheumatology of the 
Christian Medical College Hospital. The regular rheumatology clinics function twice a 
week and have an average attendance of 200 patients with rheumatological diseases each 
day. In addition to this patients were also drawn from the Spondyloarthritis and crystal 
arthritis clinic. The Department provides both out-patient and in-patient care for these 
patients. Patients are drawn from all parts of the country and represent a wide area 
stretching far beyond Tamil Nadu.  
 
Study Design 
The study was a cross-sectional study. The study design and methods were approved by 
the Institutional Research Committee of the Christian Medical College, Vellore.  
 
Subjects 
All patients with Ankylosing Spondylitis attending the out-patient clinic who fulfilled the 
inclusion criteria and consented to participate in the study were recruited.  
Inclusion Criteria 
1. Age > 18 years 
2. Satisfying the Modified New York Criteria for Ankylosing Spondylitis 
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Modified New York Criteria  
1. Low back pain of at least 3 months duration, improved by exercise and not relieved by   
    rest 
2. Limitation of lumbar spine in sagittal and frontal planes 
3. Chest expansion decreased relative to normal values for age and sex 
4. Bilateral sacroiliitis grade 2-4 
5. Unilateral sacroiliitis grade 3-4 
Patients require one radiological criterion and one clinical criterion for diagnosis. 
Exclusion Criteria 
1. Patients on bisphosphonates or on other medications which influence bone metabolism 
2. Severe infections or co-morbidities 
3. Patients with other diseases, which may influence bone density 
 
Subject Enrolment and Conduct of Study 
Participants were recruited in this study from the out patient clinics of the Department of 
Medicine II and Clinical Immunology and Rheumatology in Christian Medical College, 
Vellore. Patients over 18 years of age with AS who satisfied the inclusion criteria were 
approached for enrollment. Informed consent was obtained from these patients for 
inclusion in the study, following which base line parameters were assessed. This included 
anthropometric measurements, Finger floor distance, Schober’s test, Occiput wall 
distance and a detailed history of previous therapy. BASDAI, BASFI, BAS-G scores 
were determined utilizing standard forms for the same. These indices have been 
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standardized and evaluated as published previously(50-52). The forms used are included 
in Annexure 2. These are self-administered questionnaires and were filled by the patients 
at time of inclusion in the study. Blood was collected for Complete blood counts, Liver 
function tests, ESR and CRP. Radiographs of the Sacroiliac joints were taken in all cases. 
In addition lumbar spine radiographs were also obtained when possible. Patients then 
underwent Dual Energy X-ray Absorptiometry (DEXA) to assess bone mineral density at 
femoral neck and/or lumbar spine. Patients remained on NSAID therapy and other second 
line therapy as started prior to the commencement of the study. During the study, patients 
were given education regarding the nature of disease, prognosis, treatment and 
importance of compliance with drugs and physiotherapy.     
 
Definition of Outcomes 
Osteoporosis – Defined as T score < -2.5. 
Osteopenia – Defined as T score between –1 and –2.5 
Normal – T score above –1. 
 
Description of Metrological measurements 
Modified Schober test - Using a pen to the midpoint between the posterior superior iliac 
spines (PSIS) is marked. Then two points are identified and marked: (1) one that is 10 cm 
superior to the PSIS level on the spine, and (2) one that is 5 cm inferior to the PSIS level 
on the spine. As the patient flexes the spine as far as possible without bending the knees, 
the distance between the original and moved superior marks is measured and recorded. 
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Normal values are more than 7.5 cm. The test is interpreted as positive if the movement 
of the mark is less than 5 cm (53).  
 
Finger floor distance (FFD) – This was the distance measured between finger tips and 
floor while patient flexed his spine maximally anteriorly. This can be used as a measure 
of overall spine flexion and is useful in following up a patient.   
 
Occiput Wall Distance (OWD) – With the patient standing back to a wall, with feet, 
buttocks and shoulders touching the wall, the distance between the occiput and wall was 
measured.  
 
Chest Expansion – With the patient standing the circumference of the chest was 
measured after complete expiration and then following a maximal inspiration at the level 
of the nipples. The difference in these values was taken as the chest expansion. This is 
restricted due to the calcification of costovertebral, intercostals and sternocostal 
enthesopathic sites.   
 
Description of Disease Indices  
BASFI (Annexure II) - The BASFI(50) is a set of 10 questions designed to determine 
the degree of functional limitation in those with AS. The ten questions were chosen with 
a major input from patients with AS. The first 8 questions consider activities related to 
functional anatomy. The final 2 questions assess the patients’ ability to cope with 
everyday life. 
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A 10cm visual analog scale is used to answer the questions. This improves both the 
sensitivity of the index to change and its capacity to elicit a range of responses across the 
entire scale. The mean of the ten scales gives the BASFI score – a value between 0 and 
10. 
BASDAI (Annexure III) - Like the BASFI, the BASDAI(51) consists of 10cm visual 
analog scales used to answer 6 questions pertaining to the 5 major symptoms of AS: 
- Fatigue 
- Spinal pain 
- Joint pain / swelling 
- Areas of localized tenderness   
- Morning stiffness. 
To give each symptom equal weighting, the mean of the two scores relating to morning 
stiffness is taken. The resulting 0 to 50 score is divided by 5 to give a final 0 – 10 
BASDAI score. 
BAS-G (Annexure IV)- The BAS-G is essentially an objective way of asking the 
question: 
“How have you been over the last x months?” The BAS-G consists of two questions 
which ask patients’ to indicate, on a 10cm visual analog scale, the effect the disease has 
had on their well being over the 
– last week 
– last six months. 
The mean of the two scores gives a BAS-G score of 0 –10. The higher the score, the 
greater the perceived effect of the disease on the patient’s well being. 
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Figure 2. Radiograph showing syndesmophytes and bridging ossification. 
 
 
 
 
 
 
 
 
Figure 3. Radiograph showing bilateral sacroiliiits. 
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Grading of Sacroiliac Radiographs (54) 
Grade 0 - Normal 
Grade 1 – Fuzzy margins 
Grade 2 – Definite irregularity of joint lining, but no narrowing of space: rather 
sometimes there may be widening due to inflammatory fluid collection  
Grade 3 – Definite irregularity of joint lining, with narrowing of joint space, but not 
completely fused. 
Grade 4 - Complete Ankylosis 
 
Dual Energy X Ray Absorptiometry (DEXA) 
DEXA utilizes an X ray tube to produce photons with two distinct photoelectric peaks. 
The basic principle is that when the beam passes through a region of the body containing 
both bone and soft tissue, attenuation occurs at both energy peaks. Since one of these 
peaks is preferentially attenuated by bone the contribution by soft tissue can be 
mathematically calculated and subtracted. This ability to separate bone from soft tissue, 
allows the quantification of bone density in areas of the skeleton surrounded by large or 
irregular masses of soft tissue.  
Since X ray tubes produce a beam with a wide range of photon energies machines use 
methods to produce two distinct photoelectric peaks. Certain manufacturers use K-edge 
filters, while others use alternate pulses of varying voltage to the X ray tube. 
DEXA is an improvement on the previous technique of Dual Photon Absorptiometry as it 
requires shorter time, reduced radiation exposure, is less expensive and has greater 
precision.  
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Two types of DEXA scanners are available – “pencil beam or “fan-array”. Pencil beam 
scanners employ a narrowed X ray beam that moves in tandem in a rectilinear pattern 
with the detector. Fan-array scanners utilize a much broader beam and an array of 
detectors, leading to shortened scan times with enhanced resolution. The machine used 
during this study was a Hologic Delphi – W, which is a fan-arrray scanner (55). 
 
Sample Size Calculation 
The sample size for the study calculated using an expected prevalence of osteoporosis in 
AS of 15% with a precision of 7.5% was 100 subjects. The usual precision utilized is 
between 5-10% and hence for this study a mid-way value of 7.5% was chosen. The 
assumed prevalence of osteoporosis was based on previous studies showing a range from 
4 to 31 % in AS. Most of these studies employed sample sizes ranging from 30-80. 
Sample Size Formula – n =  4 p (1-p) / d2  
Where n – sample size, p- estimated prevalence and d – precision.   
 
Statistical Analysis 
Data entry was done using the Statistical Package for the Social Sciences (SPSS) 
software package (version 15). Descriptive statistics were calculated using SPSS 
software. Prevalence of osteoporosis was calculated for the entire sample utilizing  
Western controls.  Prevalence of osteoporosis was also ascertained in groups divided 
according to disease duration, severity and treatment and correlation coefficients for the 
various parameters in relation to osteoporosis were calculated. Logistic regression 
analysis was also performed to assess which variables independently affected BMD. 
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Figure 4 Hologic DEXA Machine  
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RESULTS 
Demographic Characteristics 
Age 
The mean age of the study population was 36 (±11) years. The ages ranged from 18 to 64 
with the majority of the people being between the age of 20 and 40.  
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Figure 5 – Histogram showing distribution of age among study population 
 
Sex 
The majority of patients in the study population were male (90%). The male : female 
ratio was 10:1.  
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Region of origin  
The distribution of patients by state of origin is shown in table 2. 
 
Table 2. State of Origin 
State Number 
Tamil Nadu 12 
West Bengal 81 
Assam   2 
Tripura   1 
Madhya Pradesh   4 
 
Figure 6. Distribution by region of origin 
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BMI 
The mean BMI of the population was 21.5(±4.15) kg/m2 and ranged from 14.6 to 32.4 
kg/m2.  
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Duration of Disease 
The median duration of disease for the study population was 8 years. This ranged from a 
minimum of 1 year to a maximum of 34 years. In Table 3 we can see that there is an even 
distribution of the patients among the three groups – those with disease duration less than 
5 years, duration 5 to 10 years and more than 10 years. 
      Table 3 – Distribution of study population by duration of disease 
Duration of Disease Number 
Less than 5 years 32 
5 – 10 years 35 
>10 years 33 
Figure 7. Distribution by duration of disease
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Treatment with sulfasalazine ± methotrexate 
56 % of people in the study population had received sulfasalazine ± methotrexate at 
initial presentation. The mean duration of treatment was 1.5 (±2.3) years. Subsequently 
all patients were initiated on both sulfasalazine and methotrexate.  
 
Steroid Use prior to presentation 
The prevalence of steroid usage was fairly low in the study population. Only 10 % of the 
population had received steroids at any point of time during their illness.  
 
Disease Indices 
BASDAI – Mean BASDAI for the population was 1.98(±1.2).The values ranged from 0 
to 4.8 The mean BASDAI did not differ significantly between the three groups based on 
disease duration. 
BASFI – Mean BASFI was 5.22(±2.4). The values ranged between 0 and 9,75. The mean 
BASFI did not differ significantly between the three groups based on disease duration.   
BAS – G – Mean BAS G was 1.2(±0.55), with a range from 0 to 2. 
 
Laboratory Studies  
ESR  - Mean ESR was 46 (±32) with a range of 2-135. 
ESR showed no correlation with disease activity as assessed with BASDAI. 
CRP – Mean CRP was 32.8 (±38) and a range of 0-164 
CRP showed a positive correlation with the BASDAI. (r=0.258,p=0.04) 
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Radiological Studies  
SI joint X ray  
All patients had clear evidence of radiological SI joint involvement. Mean grade of 
sacroiliitis was 3.22 ± 0.728.  
F i g u r e  8 .  D i s t r i b u t i o n  b y  s e v e r i t y  o f  S a c r o i l i i t i s
1 8
4 4
3 8
0
5
1 0
1 5
2 0
2 5
3 0
3 5
4 0
4 5
5 0
G r a d e  2 G r a d e  3 G r a d e  4
G r a d e  o f  s a c r o i l i i t i s
N
um
be
r o
f p
at
ie
nt
s
 
 
Spine X ray 
Spinal radiographs were available for 65 of the patients. 10 patients (15%) had evidence 
of vertebral compression fractures. Syndesmophytes were seen in 30 patients (46%).  
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Metrological Data 
The following is a summary of the metrological data for the cohort. 
Table 4 – Summary of metrological data for study population 
Parameter Mean ± Std deviation Range 
Finger floor distance 22.8 ± 16.9 cm 0 – 65 cm 
Schober’s  2.64 ± 1 cm 0 – 5 cm 
Occiput wall distance  2.9 ± 4.6 cm 0 – 24 cm 
Chest expansion 2.65 ± 0.8 cm 1 – 5 cm 
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BMD  
One hundred subjects underwent BMD measurement using DEXA. Utilizing WHO 
criteria for osteoporosis, overall 37% were found to have osteoporosis either at the spine 
or the hip.  
BMD at lumbar spine  
Ninety two subjects underwent BMD measurement of spine using DEXA. 
Mean BMD at lumbar spine for the population was 0.903 (±0.17) gm/ sq cm.  
The mean T score was –1.72 (±1.52). 
Utilizing Caucasian controls as provided by the manufacturer. 
Osteoporosis was seen in 35 subjects out of 92 (38%). 
Osteopenia was seen in 31 subjects out of 92 (33%). 
Difference in osteoporosis between men and women  
Women - At the spine, 4 women out of 9 (44%) had osteopenia and 3 women out of 9 
(33%) had osteoporosis utilizing Caucasian controls 
Men – At the spine, 28 men out of 83 (33%) had osteopenia, while 32 men out of 83 
(38%) had osteoporosis utilizing Western controls. Osteoporosis in men and women with 
AS was not significantly different.  
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Figure 9.  
Osteoporosis at the spine in relation to gender
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Correlation with disease duration  
There was a positive correlation of disease duration with BMD at the spine. The 
Pearson’s correlation coefficient (r) was 0.251 with a 2 tailed p value of 0.016 which is 
significant. 
 
Table 5 – Osteoporosis at the spine in relation to disease duration  
Duration Osteopenia (n=31) Osteoporosis(n=35) 
Less than 5 years (n=31) 11(36%) 13(42%) 
5 to 10 years (n=32) 10(31%) 15(46%) 
> than 10 years (n=29) 10(34%) 7(24%) 
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Figure 10. 
 
Osteoporosis at the spine in relation to disease duration
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As can be seen from table 5, there is a lower percentage of patients with osteoporosis and 
osteopenia in the patients with disease duration above 10 years as compared with the 
other two groups.  
 
Correlation with BMI  
There was a moderate positive correlation of BMD with BMI with r=0.405 and p<0.001. 
 
 
Correlation with disease activity (BASDAI) 
There was a weak negative correlation of BMD at the spine with disease activity as 
measured by the BASDAI. r was –0.209 and the two tailed p value was 0.047. 
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Correlation with Functional status  (BASFI) 
There was no correlation between BMD at the spine and functional status as measured by 
the BASFI. However in the group of patients with disease duration less than 5 years there 
was a moderate negative correlation of BMD at the spine with BASFI (r= –0.374, 
p=0.04). A similar relationship was however not seen in patients with disease duration of 
more than 5 years.    
 
Correlation with ESR, CRP 
There was no correlation of BMD with ESR (p=0.64) . However the correlation with  
CRP (p=0.05) attained significance.  
 
Correlation with Radiology  
There was no correlation of BMD at the spine with either the grade of sacroiliitis 
(p=0.272) or the presence of syndesmophytes (p=0.357).  
 
Correlation with prior treatment  
There was no correlation of BMD with previous treatment with sulfasalazine/ 
methotrexate or steroids (p=0.85). 
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Table 6 . – Associations of Osteoporosis at the spine in AS (Univariate analysis) 
Parameter  Odds Ratio 95% CI P value 
BMI > 18 0.270 0.1-0.76 0.013 
Duration <15 years 5.68 1.1-25.5 0.028 
CRP>20 2.01 0.88-4.77 0.110 
BASDAI <3 0.472 0.16-1.3 0.14 
BASFI <7 0.88 0.32-2.27 0.751 
FFD >15cm 2.25 0.89-5.66 0.08 
DMARD>1 yr 1.15 0.45-2.9 0.761 
 
 
Utilizing a univariate analysis, we find that patients with BMI>18 had significantly lower 
occurrence of osteoporosis at the spine, while a duration of disease less than and upto 15 
years seems to be associated with osteoporosis at the spine. None of the other variables 
given above are associated with osteoporosis at the spine.  
On entering the values with p<0.15 in a multivariate regression analysis, BMI<18 (OR 
0.322,p=0.04) and duration upto 15 years (OR 5.34, p=0.03), still correlate with 
osteoporosis at the spine, hence suggesting that these are independent associates of 
osteoporosis. 
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BMD at Hip 
Ninety six of the patients had BMD measured at the hip. Mean BMD at the hip for the 
population was 0.84 (±0.15) gm/sq cm. The mean T score was –1.2 (± 1.02)  
Utilizing Western Controls: 
Osteoporosis  was seen in 8 subjects out of 96 (8.3%). 
Osteopenia was seen in 55 subjects out of 96 (57%).  
 
Difference in osteoporosis between men and women 
There was no significant correlation between sex and osteopenia (p=0.43) or osteoporosis 
(p=0.374)  
 
Table 7 – Distribution of osteoporosis and osteopenia at the hip against sex. 
 
Sex Osteopenia  
(n=55) 
 
Osteoporosis 
(n=8) 
Male (n=86) 51(56%) 8(8%) 
Female (n=10) 4(40%) 0(0%) 
 
 44
Figure 11. 
Osteoporosis at the hip in relation to gender
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Correlation with disease duration  
Table 8 – Osteoporosis at the hip utilizing Western controls in relation to disease duration 
 
Duration Osteopenia (n=54) Osteoporosis(n=8) 
Less than 5 years (n=31) 15(48%) 1(3%) 
5 to 10 years (n=35) 16(45.7%) 4(11.4%) 
> than 10 years (n=30) 23(75%) 3(10%) 
 
 
 
The number of patients with osteoporosis and osteopenia was greatest in the group with 
duration of disease more than 10 years. 
There was a negative correlation of BMD at hip with disease duration. r was –0.209 and 
this was significant. (p value – 0.046). 
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Figure12. 
Osteoporosis at the hip in relation to disease duration
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Correlation with BMI 
There is a positive correlation between BMI and BMD at hip, r=0.322, p=0.001. 
 
Correlation with disease activity (BASDAI) 
There was no correlation between disease activity as assessed by the index BASDAI and 
BMD at the hip. (p-0.103) 
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Correlation with Functional status  (BASFI) 
There was a moderate negative correlation between the score on the BASFI and the BMD 
at the hip. The Pearson’s correlation coefficient was –0.380 with a p value < 0.001.  
 
Figure 13. – Scatter plot of BASFI against BMD hip. 
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Correlation with FFD 
There was a strong negative correlation between FFD and BMD at the hip, r=-0.47, 
p<0.001.  
 
Correlation with ESR, CRP 
There was no correlation between BMD at hip and ESR (p-0.076) and CRP(p-0.611) 
values for the subjects. 
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Correlation with Radiology  
There was a positive correlation between presence of syndesmophytes and the occurrence 
of osteoporosis or osteopenia at the hip.  64 patients had imaging of the lumbosacral 
spine. Of these patients 29 were found to have syndesmophytes while the remaining did 
not. In the group with syndesmophytes, 86.2% of the patients had either osteoporosis or 
osteopenia while in the group without syndesmophytes only 51.4% had either 
osteoporosis or osteopenia at the hip (p-0.005). 
Table 9 – Crosstabulation between occurrence of Osteoporosis/osteopenia at the hip 
and syndesmophytes 
 Syndesmophytes (n=29) No Syndesmophytes(n=35) 
Osteoporosis or osteopenia 
present(n=43) 
25(86.2%) 18(51.4%) 
Osteoporosis or osteopenia 
absent (n=21) 
4(13.8%) 17(48.6%) 
 
Crosstabulation between osteoporosis at the hip and syndesmophytes also revealed a 
positive correlation, that was significant (p- 0.012).  
Effect of Treatment 
There was no correlation between osteoporosis at the hip and previous treatment with 
Sulfasalazine ± methotrexate or steroids. r – 0.15 (p-0.886).  
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DISCUSSION 
        This is the first study to assess occurrence of osteoporosis in AS in India. The world 
over, nine other studies have addressed this issue. The present study is the second largest 
in this series. Our cohort had a majority of male patients, with a male : female ratio of 
10:1. This was fairly high compared to other sources in literature, quoting ratios ranging 
from 4-10:1(1, 4). The reason for this discrepancy is unclear but may be related to gender 
differences in health seeking behavior. The mean age of the cohort was 36 years, with a 
majority of subjects being in the age group of 20-40 years. The majority (90%) of the 
patients hailed from North India. This cannot be fully explained by the pattern of 
attendance in our out-patient clinics. Earlier studies have shown that HLA B27 
prevalence is higher among North Indians as compared to South Indians(56). In one study 
the prevalence in North India was found to be 6% while in South Indians it was less than 
5%(56, 57). In another study the prevalence among North Indian subjects was 4.6% as 
against 1.1% in South Indian subjects (58). This discrepancy may help to explain the 
predominance of North Indian patients in our cohort.  
          The prevalence of osteoporosis at the spine, calculated utilizing Western controls 
was 38%, while the prevalence of osteopenia was 33%. This is similar to most other 
series in literature. The most striking fact was that osteoporosis tended to occur early in 
the disease. At the spine, 42% of patients with disease duration less than 5 years had 
osteoporosis. It was also noted that the occurrence of osteoporosis at the spine declined 
with increasing disease duration. This concurs with observations in other studies that 
showed a positive correlation of BMD at the spine with disease duration(10). The 
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probable cause for this has been postulated to be an artefactual increase due to paraspinal 
ossification late in the disease.  
           The prevalence of osteoporosis at the hip, utilizing Western controls was 8.3%, 
while the prevalence of osteopenia was 57%. Thus, it appears that bone loss is more 
marked at the spine than at the hip in patients with AS. This conflicts with a recent study 
by Karberg et al (10) where it was found that osteopenia and osteoporosis were higher at 
the hip than at the spine especially in patients with a disease duration of more than 10 
years. The reason for this discrepancy is not apparent, but may suggest racial differences 
in patterns of bone loss. These findings, however, are consistent with a study by 
Devoglear et al(20) where the largest reduction in spinal BMD as measured by Dual 
Photon Absorptiometry was seen in men with early AS. In patients with more advanced 
disease, however, BMD was found to be no different from that of controls in other 
studies. However QCT showed low bone mass in some of these patients(21). Similar 
results were reported by Maghraoui et al(5). In our study BMD at the hip correlated 
negatively with disease duration, which is in keeping with earlier studies (5,10,20).  
         These observations suggest that the investigation of choice to detect osteoporosis in 
patients with AS would depend on disease duration. In early disease (<10 years duration) 
a BMD of the spine would be ideal, while in later stages both a BMD spine and hip 
would be required. In later stages of the disease a QCT of the spine may also be useful, 
although it is not yet a standard means of assessment for osteoporosis. 
 One drawback of the study was that T scores were calculated against Western 
controls. There is conflicting data as to whether BMD in Indian subjects is the same as 
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their Western counterparts. It may have been more informative if T scores could have 
been calculated using normative Indian data.    
 The prevalence of osteopenia was 33% at the spine and 57% at the hip. Out of 
these, 17% at the spine and 12% at the hip had T score below –2.0. Studies are 
conflicting as to whether patients with osteopenia require pharmacological therapy (59-
61). Guidelines by various organizations are also unclear on the same (59-61). While the 
National Osteoporosis Foundation(59) and the American Association of Clinical 
Endocrinologists(60) suggest  the consideration of pharmacologic therapy for women 
with T scores that are less than –1.5 with additional risk factors, the North American 
Menopause Society(61) recommends that this intervention be deferred until the T score is 
lower (–2.0 to –2.5) even with additional risk factors. Thus, it may be prudent to consider 
pharmacological therapy in the patients with T score less than –2.0. Utilizing this cutoff, 
more than 50% of patients with AS would require pharmacological therapy to improve 
BMD, in addition to lifestyle changes. 
          BMI was found to correlate positively with BMD at the hip and the spine. Using 
regression analysis, it was found that BMI >18 kg/m2 was protective for the development 
of osteoporosis at the spine (OR-0.322, p-0.04). Similar findings have been reported in an 
earlier study by Maghraoui et al (5). The relationship between BMI and osteoporosis has 
been well established in postmenopausal osteoporosis(62). A similar positive correlation 
of BMD and BMI seems to exist in patients with AS.  
            BMD also correlates with metrological measurements. There is a negative 
correlation between Finger Floor Distance and BMD at hip. It has been shown in an 
earlier study that vertebral fractures are associated with restriction of spinal movement 
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(41). Thus, worse metrological measurements may serve as markers for osteoporosis at 
the hip, prompting screening in those with poor spinal mobility.  
             There was a weak correlation of BASDAI and CRP with osteoporosis at the 
spine. However on regression analysis neither of these were independently associated 
with osteoporosis at the spine. At the hip there seems to be no significant correlation of 
disease activity as measured by BASDAI or ESR and CRP with osteoporosis. Similar 
results were found by Camargo et al (25) in a study done on 30 patients. Maghraoui et al 
(5) in their study on 80 patients concluded that osteoporosis was more in patients with 
more severe and active disease. However, this was based on a correlation between bone 
resorption markers and ESR and CRP. They did not find a correlation between BMD and 
either clinical activity or ESR and CRP. Thus, disease activity does not appear to 
correlate with osteoporosis at the hip. At the spine, however, more active disease may be 
a predictor for osteoporosis. Based on this data we recommend that all patients 
irrespective of activity of disease should be screened for osteoporosis. 
           There was a correlation between functional status as measured by BASFI with 
osteoporosis at the hip. This may be related to chronicity of disease, as well as the fact 
that immobilization due to worse functional status may lead to worsening of osteoporosis. 
In turn, the worsening osteoporosis may also lead to worsening of symptoms and thus 
worsen functional status. There are, however, no reports of such a relationship in 
previous studies. The BASFI may thus serve as a simple tool to identify patients who 
may be at increased risk for osteoporosis at the hip. We advocate the routine use of this 
tool in all patients with AS.  
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            A striking correlation was found between syndesmophytes on the spinal 
radiograph and osteoporosis or osteopenia at the hip (86% vs 51%).  This concurs with 
the study done by Karberg et al (10), where 55 patients were studied and it was found that 
among patients with syndesmophytes, occurrence of osteoporosis at the hip was 31% as 
compared to 14% among those without syndesmophytes. Therefore in patients with 
syndesmophytes on the spinal radiograph, a BMD of the hip would be strongly 
advocated. 
          It was found in this study, that treatment with sulfosalazine ± methotrexate did not 
affect occurrence of osteoporosis. However only half of our patients had been on these 
drugs and this may hence be inadequate to comment. This probably reflects the fact that 
unlike rheumatoid arthritis, most DMARDS have not been shown to have much benefit in 
patients with AS(1). Given the probable mechanism of osteoporosis being mediated by 
the same inflammatory mediators causing the disease manifestations, medications that 
target these pathways would be expected to halt bone loss(49). Since our cohort did not 
comprise any patients who had been on long-term biological therapy, the effect of these 
medications on osteoporosis could not be assessed.  
        In conclusion, this study demonstrates that osteoporosis and osteopenia are 
common in Indian patients with AS. Recognizing and treating these complications will 
help in improving morbidity associated with the disease. Since they occur early in the 
disease, all patients should undergo screening at presentation. DEXA is still the 
investigation of choice due to easy availability, low cost and standardization. It would be 
advisable to obtain DEXA of spine in early disease and both spine and hip later in the 
disease. 
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CONCLUSIONS 
• Osteoporosis at the spine was found in 38%, while at the hip, it was found in 
8.3% of Indian patients with Ankylosing Spondylitis. Osteopenia at the spine was 
found in 33%, while at the hip, the corresponding figure was 57%. This data 
suggests that osteoporosis is a common complication of AS and almost two thirds 
of AS patients have abnormal BMD.     
• Bone loss occurs early at the spine and can be seen within the first 5 years of 
disease onset (42%). Thus, in early cases, BMD at the spine is required to pick up 
osteoporosis, but later in the disease, BMD hip will help to detect patients who 
have an artefactual increase in spinal BMD due to paraspinal ossification.  
• BMD at the spine (r=0.4,p<0.001) and hip (r=0.32,p=0.001) correlates positively 
with BMI. Thus AS patients with higher BMI are at less risk to develop 
osteoporosis. 
• BMD at the hip correlates inversely with functional status as measured by BASFI 
(r=-0.38,p<0.001) and also with FFD (r=-0.47,p<0.01).  
• Paradoxically, syndesmophytes are strongly associated with osteoporosis or 
osteopenia at the hip (p=0.012). Thus utilization of simple tools such as the 
BASFI as well as metrological measurements such as FFD may help identify AS 
patients requiring BMD measurement. 
• Based on this study, we recommend that all AS patients at diagnosis should have 
spinal BMD measurements, and in patients with disease duration more than 5 
years or having syndesmophytes, this should be coupled with BMD measurement 
at the hip.   
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Objectives of the study: 
To determine the occurrence of osteoporosis among a cohort of patients with Ankylosing 
Spondylitis(AS) and to assess whether disease indices, demographic factors, disease 
duration, prior treatment or parameters of inflammation have an association with 
osteoporosis in AS. 
Methods: 
One hundred patients with AS were enrolled in the study. Anthropometric measurements, 
metrological measurements and a detailed history were obtained. BASDAI, BASFI, 
BAS-G scores were determined. Blood was collected for Complete blood counts, Liver 
function tests, ESR and CRP. Sacroiliac radiographs were taken. In addition lumbar spine 
radiographs were obtained when possible. Patients underwent Dual Energy X-ray 
Absorptiometry (DEXA) to assess bone mineral density at femoral neck and/or lumbar 
spine. The prevalence of osteoporosis was then calculated and statistical analysis was 
done to assess the correlates of osteoporosis.  
 
Results: 
            One hundred subjects were enrolled during the 24 months from March 1, 2005 to 
April 1, 2007. The mean age was 36 years with a male:female ratio of 10:1. The median 
duration of disease was 8 years (1-34 years). At the spine 38% of subjects had 
osteoporosis while an additional 33% had osteopenia. However, at the hip osteoporosis 
was found in 8% of subjects with osteopenia in 57%. There was a significant positive 
correlation of BMD at the spine with disease duration(r=0.252,p=0.016) while BMD at 
the hip showed a negative correlation (r=-0.209,p=0.046).  Multivariate analysis revealed 
that osteoporosis at the spine was significantly less in patients with BMI>18 (OR-0.32, 
p=0.04) while it was positively associated with a disease duration upto 15 years (OR-
5.34, p-0.03). At the hip BMD showed a negative correlation with BASFI (r=-0.38, 
p<0.001) as well as FFD (r=-0.47, p<0.001). Osteoporosis at the hip was significantly 
more in patients with syndesmophytes (p=0.012). There was no correlation between 
osteoporosis at the spine or hip with disease activity, laboratory parameters of 
inflammation or previous treatment.  
 
Conclusion 
Osteoporosis of spine (38%), rather than that of hip (8%) is prevalent in Indian patients 
with AS.  Osteoporosis at the spine occurs early in the disease. At the spine, a BMI>18 is 
protective, while a shorter duration of disease (<15 years) is predictive of osteoporosis. 
At the hip, worse functional status and metrological measurements along with the 
presence of syndesmophytes are predictive of osteoporosis.   
 
APPENDIX I 
 
DATA COLLECTION  FORM  
 
1. NAME : 
 
2. AGE : 
 
3. SEX: 
 
4. ADDRESS: 
 
 
5. HOSPITAL NUMBER : 
 
6. DURATION OF ILLNESS : 
 
 
7. HISTORY OF TREATMENT : 
 
 
 
 
 
 
8. BASDAI : 
 
9. BASFI : 
 
10. BAS-G: 
 
11. SIGNIFICANT MEDICAL HISTORY : 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NSAID USE -                                Dose                Duration                       Toxicity 
Indomethacin 
Naproxen 
Celecoxib 
Diclofenac 
Aceclofenac 
Others 
 
Biologicals 
 
Sulfosalazine 
 
Methotrexate 
 
Calcium 
 
Vitamin D 
 
Proton pump inhibitors 
 
Steroids 
ORAL 
 
PULSE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PHYSICAL EXAMINATION 
 
HEIGHT : 
 
WEIGHT: 
 
BMI: 
 
SWOLLEN JOINTS : 
 
 
 
ENTHESOPATHY:  
(SITES) 
 
FINGER TO FLOOR DISTANCE: 
 
CHEST  EXPANSION  
 
SCHOBERS MEASUREMENT: 
 
OCCIPUT TO WALL DISTANCE: 
 
 
Psoriasis            - Y           N 
 
Inflammatory bowel disease – Y     N 
 
Extraarticular manifestations –  
UVEITIS 
PULMONARY FIBROSIS 
CARDIAC 
RENAL 
CNS 
VERTEBRAL FRACTURES 
DACTYLITIS  
 
 
 
 
 
 
 
 
 
 
LAB STUDIES : 
 
ESR: 
 
CRP : 
 
HB:                                   TC : 
 
Plt :                                    Creat: 
 
AC: 
PC:  
 
LFT :  
 
 
DEXA : 
 
XRAY SI JOINT  : Grade     I               II        III         IV     Nil 
 
Spine X Ray – Syndesmophytes 
                        Loss of lumbar lordosis 
                        Squaring of vertebrae 
                        Decreased vertebral height 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Researcher: 
Date: 
 
 
 
 
 
 
 
 
 
APPENDIX II 
 
 
 
 
APPENDIX III 
 
 
 
 
 
 
APPENDIX IV 
 
 
 
 
 
 
 
